Evaluating CAR-T KYV-101 for Generalized Myasthenia Gravis

Kyverna Therapeutics is currently developing the chimeric antigen receptor T-cell (CAR-T) therapy KYV-101 for the treatment of various autoimmune diseases. Among several trials the company is conducting is the phase 2/3 KYSA-6 clinical trial…